Stemline therapeutics switzerland gmbh

Author: poyk

August undefined, 2024

網頁Passionate and very dynamic person, my talent is to build bridges between various stakeholders by using all communication channels at their bests. With 10+ years of experience with BigPharma companies, my …

Stemline Therapeutics LinkedIn

網頁Monja Sieber is an attorney at law who works as Legal & Compliance Manager at A. Menarini GmbH, Zurich, an international pharmaceutical company with its own research centers specialised in the development and marketing of innovative products in the field of primary and secondary care as well as medical devices. She is responsible for legal and … 網頁Ob Praktikum, Direkteinstieg oder Berufserfahrene – unser Karriereportal bietet unterschiedliche Einstiegsmöglichkeiten. Hier geht’s zu Ihrer Bewerbung:… bargain jordan shoes

Stemline Therapeutics Switzerland GmbH Company Profile Zug, …

網頁2024年4月27日 · Stemline Therapeutics Switzerland GmbH is active according to the commercial register. The company with the UID number CHE-166.416.225 was founded … 網頁Free and open company data on Switzerland company Stemline Therapeutics Switzerland GmbH (company number 1409641), Grafenaustrasse, 3, Zug, 6300 Company Number 1409641 Status Aktive Company Type Gesellschaft mit beschränkter Haftung Jurisdiction 網頁Kontaktieren Sie Stemline Therapeutics Switzerland GmbH Grafenaustrasse 3 6300 Zug Schweiz Telefonnummer anzeigen Firma anrufen ×---Service Anrufkosten * Diese … suyoto bojonegoro

Stemline Therapeutics LinkedIn

網頁Funding. Stemline Therapeutics has raised a total of $107.1M in funding over 5 rounds. Their latest funding was raised on Jan 15, 2024 from a Post-IPO Equity round. Stemline Therapeutics is registered under the ticker NASDAQ:STML . Their stock opened with $10.00 in its Jan 29, 2013 IPO. 網頁Nov 2013 - Mar 20162 years 5 months. Munich Area, Germany. Business unit head, directly responsible and accountable for c.30M€ business, leadership of a cross-functional team including more than 90 people, as well as lead for the implementation of organisational redesign in the preparation of the Lixiana (edoxaban) launch. Reporting to DACH GM. su yuan novel網頁Wir freuen uns, Equipnet und Stemline Therapeutics Switzerland als neue Mitglieder und Informa als neues Fördermitglied der BIO Deutschland begrüßen zu dürfen. Equipnet … bargain jokes

"網頁Free and open company data on Switzerland company Stemline Therapeutics Switzerland GmbH (company number 1409641), Grafenaustrasse, 3, Zug, 6300 Company Number … " - Stemline therapeutics switzerland gmbh

Stemline therapeutics switzerland gmbh

Roger Bachmann – Practice Lead Life Sciences Recruitment – Brainfield Switzerland …

網頁2024年4月26日 · EUROPEA.Market AnalysisCurrent & Future AnalysisChanging Demographics to Propel Market GrowthTable 22: European Population By Age Group (2013, 2024 & 2040): Percentage Share Breakdown of Age ... 網頁Stemline Investor Relations Peter McDonald Stemline Therapeutics, Inc. 646-502-2307 Email: [email protected] Media Relations Andy Brimmer / Scott Bisang Joele Frank, Wilkinson Brimmer Katcher 212-355-4449 (Traduzione: in caso di conflitto vale

Did you know?

網頁Stemline Therapeutics Switzerland GmbH, Zug, Schweiz, Schweizer Handelsregister CHE-166.416.225: Netzwerk, Wirtschaftsinfos Das Dossier ist eine druckfähige PDF … 網頁2024年5月4日 · Stemline Contacts Investor Relations Peter McDonald Stemline Therapeutics, Inc. 646-502-2307 Email: [email protected] Media Andy Brimmer / Scott Bisang Joele Frank, Wilkinson Brimmer Katcher ...

網頁Info. Remote Life Science Recruiter mit Erfahrung im mittleren Management (Manager to VP). Extensives Netzwerk zu Kandidaten/innen in den Bereichen Regulatory Affairs, Verkauf (Sales), Marketing, Medical Affairs & Data Science. Zu erreichen über Linkedin oder per Email: [email protected]. 網頁Company Overview. Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics. The goal of our …

網頁Stemline Therapeutics Switzerland GmbH Grafenaustrasse 3 6300 Zug Contact Phone:-Fax:-Website:-e-mail:-Location Print content Advertisement Advertisement SOGC … 網頁Le représentant européen désigné de Stemline Therapeutics Inc. et de Stemline Therapeutics Switzerland GmbH conformément à l'article 27 du RGPD est A. Menarini …

網頁Find company research, competitor information, contact details & financial data for Stemline Therapeutics Switzerland GmbH of Zug, ZUG. Get the latest business insights from …

網頁Stemline Therapeutics Switzerland GmbH is a Limited Liability Company based in Zug, in the canton of Zug, founded in 2024. Its identification number UID is CHE-166.416.225. It … su y snowboard網頁The designated European representative of Stemline Therapeutics Inc. and Stemline Therapetutics Switzerland GmbH pursuant to Article 27 of the GDPR is A. Menarini Industrie Farmaceutiche Riunite S.r.l., located in Florence, Via Sette Santi 1. bargain julian fashion網頁Stemline Therapeutics GmbH Grafenaustrasse 3, CH-6300 Zug Switzerland Founded Date August 1, 2003 Email Address [email protected] [email protected] [email protected] [email protected] Phone Number +18773327961 ... suyoshi rovigo menu網頁2024年11月11日 · Stemline Therapeutics. 18,465 followers. 2mo Edited. Stemline Therapeutics, a subsidiary of MENARINI Group, Receives U.S. FDA Approval for the … suyzd-01網頁2024年5月4日 · Stemline Contacts Investor Relations Peter McDonald Stemline Therapeutics, Inc. 646-502-2307 Email: [email protected] Media Andy Brimmer / Scott Bisang Joele Frank, Wilkinson Brimmer Katcher ... bargain juicers網頁Stemline Therapeutics Switzerland GmbH Grafenaustrasse 3 6300 Zug Switzerland Tel. +41 41 710 01 16 www.stemline.com eventi), trattiamo le informazioni necessarie per l'esecuzione delle prestazioni contrattuali o per l'esecuzione di misure precontrattuali, ad suy tim kcb網頁Stemline Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entdeckung, den Erwerb, die Entwicklung und die Vermarktung von onkologischen Therapeutika konzentriert. Das Unternehmen entwickelt etwa drei Produktkandidaten im klinischen Stadium, darunter SL-401, SL-701 und SL-801. su young kim korea